Verastem, Inc. (NASDAQ:VSTM) Given “Buy” Rating at HC Wainwright

Verastem, Inc. (NASDAQ:VSTM)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Thursday, September 7th, MarketBeat Ratings reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $6.50. HC Wainwright’s price target suggests a potential upside of 84.84% from the company’s previous close.

Several other research analysts have also recently issued reports on VSTM. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 target price on shares of Verastem in a report on Thursday, May 11th. Cann reaffirmed a “buy” rating and issued a $2.00 target price on shares of Verastem in a report on Thursday, May 11th. Oppenheimer Holdings, Inc. set a $6.00 target price on shares of Verastem and gave the stock a “buy” rating in a report on Wednesday, May 10th. Zacks Investment Research cut shares of Verastem from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $1.50 target price on shares of Verastem in a report on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $5.04.

Verastem (VSTM) opened at 5.41 on Thursday. Verastem has a 12-month low of $1.05 and a 12-month high of $5.71. The company’s 50-day moving average price is $3.88 and its 200-day moving average price is $2.63. The company’s market cap is $200.13 million.

Verastem (NASDAQ:VSTM) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Equities analysts anticipate that Verastem will post ($1.38) earnings per share for the current year.

WARNING: This piece of content was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://ledgergazette.com/2017/09/17/verastems-vstm-buy-rating-reiterated-at-hc-wainwright.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its holdings in shares of Verastem by 20.0% during the first quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock valued at $2,539,000 after purchasing an additional 204,400 shares during the last quarter. Vanguard Group Inc. increased its holdings in Verastem by 10.3% during the second quarter. Vanguard Group Inc. now owns 1,143,642 shares of the biopharmaceutical company’s stock valued at $2,493,000 after buying an additional 107,029 shares during the last quarter. Artal Group S.A. purchased a new stake in Verastem during the second quarter valued at approximately $1,090,000. Howland Capital Management LLC increased its holdings in Verastem by 16.5% during the second quarter. Howland Capital Management LLC now owns 294,007 shares of the biopharmaceutical company’s stock valued at $641,000 after buying an additional 41,616 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Verastem by 697.6% during the second quarter. Dimensional Fund Advisors LP now owns 289,828 shares of the biopharmaceutical company’s stock valued at $632,000 after buying an additional 253,492 shares during the last quarter. 24.19% of the stock is owned by hedge funds and other institutional investors.

About Verastem

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Analyst Recommendations for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply